Verve Therapeutics
Developing gene editing therapies to lower cholesterol.
About
Verve Therapeutics is a biotechnology company focused on developing novel gene editing therapies to address cardiovascular disease. Their lead candidate, VERVE-102, is an experimental gene-editing therapy designed to permanently lower LDL cholesterol (bad cholesterol) after a single infusion. The therapy works by targeting PCSK9, a gene that plays a key role in regulating cholesterol levels. Teams look it up for Biotechnology, Gene Therapy, Cardiovascular Disease.
Frequently asked
What does Verve Therapeutics do?
Verve Therapeutics is a Biotechnology company that offers Services. Teams look it up for Gene Therapy, Cardiovascular Disease, Drug Delivery. It is based in Cambridge, Massachusetts, USA and was founded in 2018. Public records show $300M in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Verve Therapeutics raised?
Verve Therapeutics has raised a total of $300M in funding. The most recent round on record is Series D.
Where is Verve Therapeutics headquartered?
Verve Therapeutics is headquartered in Cambridge, Massachusetts, USA.
When was Verve Therapeutics founded?
Verve Therapeutics was founded in 2018.
What industry does Verve Therapeutics operate in?
Verve Therapeutics operates in Biotechnology, Gene Therapy, Cardiovascular Disease, Drug Delivery, Biotech.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.